MedTrace Logo

Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients

NCT04645420 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-09-21

No results posted yet for this study

Summary

This study assess the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after an immunomodulator agent (Apremilast) in patients with active psoriatic arthritis who are naive to treatment with a conventional synthetic DMARDs (such as methotrexate).

Conditions

Interventions

PROCEDURE

Global gene expression profiles obtained from synovial biopsies.

Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Adrien NZEUSSEU TOUKAP, MD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2023-01-10
Completion
2023-02-10

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645420 on ClinicalTrials.gov